Long term follow-up of the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.
David A BaranSaurabh KapoorJagpreet GrewalGabriela AndriesMargarita CamachoPublished in: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2023)
Tacrolimus monotherapy was compared to TAC and mycophenolate mofetil without long term steroids in the randomized Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial. Post-transplant survival at 5, 10 and 15 years in the TAC monotherapy group was 84.5%, 66.9 %, and 52.7 %, and 94.4 %, 78.2 % and 56.1 % for patients randomized to TAC / MMF (p = 0.19 logrank). Cardiac allograft vasculopathy and kidney failure were similar between groups. Immunosuppression should be individualized to avoid over treating some patients while undertreating others.